IP Library Granted Patent US 8,026,269
Granted Patent B2
US 8,026,269 · App. 12/368,245 · Granted Sep 27, 2011

Isoindoline compounds and methods of making and using the same

Assignee: Celgene Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,026,269
App. No.
12/368,245
Granted
Sep 27, 2011
Kind
B2
Abstract

The invention encompasses isoindoline compounds, pharmaceutical compositions comprising them, and methods of their use for the treatment, prevention or management of various diseases and disorders. Examples include, but are not limited to, cancer, inflammatory bowel disease and myelodysplastic syndrome.

Claims (10)

1. A method of inhibiting PDE IV comprising administering to a subject a compound of the following formula:

or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

2. A method of treating or managing a disease or disorder comprising administering to a patient a compound of the following formula:

a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein the disease or disorder is arthritis, rheumatoid arthritis, inflammatory bowel disease, asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disorder, atopic dermatitis, psoriasis, or Crohn's disease.

3. The method of claim 2 , wherein the disease or disorder is asthma, adult respiratory distress syndrome, or chronic obstructive pulmonary disorder.

4. The method of claim 3 , wherein the compound is administered via an inhaler.

5. The method of claim 2 , wherein the disease or disorder is atopic dermatitis or psoriasis.

6. The method of claim 2 , wherein the compound, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, is administered in an amount of 0.01 mg to 1000 mg per day.

7. The method of claim 6 , wherein the compound, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, is administered in an amount of 0.01 mg to 300 mg per day.

8. The method of claim 7 , wherein the compound, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, is administered in an amount of 0.01 mg to 100 mg per day.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2019
From: CELGENE CORPORATION
To: AMGEN INC.
Reel/Frame 051181/0038 →
Continuity (3)
Continuation 11820788 · Jun 19, 2007
Division 10900270 · Jul 28, 2004
Related Publication 20090148388A1 · Jun 11, 2009